| | |
| | | |
|
| |
Dear Colleague,
I hope you received my previous email about the 2nd Stem Cells for Drug Developers meeting, which will be held in Berlin on 6th-7th December. It's looking to be a meeting that cannot be missed.
Download the brochure now to find out why.
While putting together the meeting I spoke with Dr David Hay from the University of Edinburgh. He shared his thoughts about the stem cell industry and the challenges facing pharma and academia in using iPSC and ESC models in drug development.
David's insights were so interesting that I thought I’d share them with you. I’ve compiled them in to an Exclusive Interview, a snapshot of which is below.
|
| | | |
| | |
| | | |
| |
![]() | | |
| | | |
| |
| |
Q. How can pharma and academia work together more collaboratively to advance stem cells technologies into the drug discovery process?
A
. I think that pharma and academia need to discuss what information can be realistically and reliably derived using the current state of the art. Following extensive characterisation we will have an idea of the uses of our prototype technology. We then need to work together to sophisticate the technology and tailor make it to suit in house technology. This is going to involve significant investment in time as well as money, but will offer significant potential to tackle the costs associated with human drug attrition.
| | | |
|
| | |
| | |
Dr David Hay,
University of Edinburgh
| | | |
| | | |
| | | |
| | |
| | | |
David was also kind enough to share with us his comments on the recent news regarding the European Court’s decision to ban patent protection for embryonic stem cell lines.
These resources are also available to download for free on the Stem cells website.
| | | |
| | |
| | | | |
| | |
1. "Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling"
Hay et al, PNAS, 2008
2. "Rapid Communication: Generation of Functional Human Hepatic Endoderm from Human Induced Pluripotent Stem Cells"
Sullivan et al, Hepatology, 2010
Available now to download for free:
www.stemcells-drugdevelopment.com/resources
| | |
| | |
| | | |
| | |
David will be speaking at the 2nd Stem Cells for Drug Developers meeting about "Generating Metabolically Active Hepatocytes from Pluripotent Stem Cells"
His full interview is available to download for free at: www.stemcells-drugdevelopment.com
Here, you can also view the full
conference agenda, with details of David’s presentation, as well as presentations from AstraZeneca, Roche, Novartis, Abbott, Biogen Idec, GSK, AVEO Pharmaceuticals, and Fate Therapeutics, to name but a few.
Plus, there will be an in-depth workshop, focusing on: Exploiting Epigenetic Mechanisms in the Control of Stem Cell Fate
Download the brochure for a comprehensive overview of the meeting.
Register before Friday 4th November and receive up to 200 EUR off standard prices.
To claim your discount please remember to quote your priority booking code: SC2
To register, simply:
Call: +44 (0) 203 1418 700
Email: in...@hansonwade.com
Visit: www.stemcells-drugdevelopment.com
Or reply to my email and I’ll handle your registration myself.
I look forward to hearing from you and meeting you in Berlin in December.
Kind regards,
Zardia
Zardia Swift
Programme Director
Hanson Wade
| | | |
| | |
| | | | |
